Market Place
Sourcing Support
All News #Library
Biotech
Pfizer Boosts Beam Gene Editor Post Hemophilia Therapy Withdrawal
26 Feb 2026 //
BIOSPACE
After Gene Therapy Exit, Pfizer Licenses Beam Gene Editing Asset
25 Feb 2026 //
FIERCE BIOTECH
Inside Beam`s `Big Push` For In Vivo Gene Editing
21 Jan 2026 //
FIERCE BIOTECH
Wave reports AATD win, but investors lukewarm
03 Sep 2025 //
FIERCE BIOTECH
Patient Death Clouds Positive Data for Beam`s Sickle Cell Therapy
06 Nov 2024 //
BIOSPACE
Beam offloads Verve rights to Lilly for up to $600M
31 Oct 2023 //
FIERCE BIOTECH
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201
05 Sep 2023 //
PRESS RELEASE
Beam takes time to clinic;Aspen gets clearance to test Parkinson`s cell therapy
08 Aug 2023 //
ENDPTS
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
01 Mar 2023 //
PRESS RELEASE
Beam hopes to sidestep sickle cell peers with gene editing
10 Jan 2023 //
FIERCEBIOTECH
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.